These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 22299599)

  • 1. Effect of the ethinylestradiol/levonorgestrel combined oral contraceptive on the activity of cytochrome P4503A in obese women.
    Edelman A; Munar M; Elman MR; Koop D; Cherala G
    Br J Clin Pharmacol; 2012 Sep; 74(3):510-4. PubMed ID: 22299599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.
    Klipping C; Duijkers I; Parke S; Mellinger U; Serrani M; Junge W
    Drugs R D; 2011; 11(2):159-70. PubMed ID: 21679006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the selective AMPA modulator NBI-1065845 on the pharmacokinetics of midazolam or ethinyl estradiol-levonorgestrel in healthy adults.
    Lin S; Ionescu A; Maynard-Scott J; Kennedy M; Walling DP; Furey M; Singh JB
    Clin Transl Sci; 2024 May; 17(5):e13791. PubMed ID: 38700236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Midostaurin drug interaction profile: a comprehensive assessment of CYP3A, CYP2B6, and CYP2C8 drug substrates, and oral contraceptives in healthy participants.
    Sechaud R; Gu H; Rahmanzadeh G; Taylor A; Chiparus O; Sharma GK; Breitschaft A; Menssen HD
    Cancer Chemother Pharmacol; 2024 May; 93(5):439-453. PubMed ID: 38270613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial.
    Westhoff CL; Torgal AH; Mayeda ER; Stanczyk FZ; Lerner JP; Benn EKT; Paik M
    Obstet Gynecol; 2010 Aug; 116(2 Pt 1):275-283. PubMed ID: 20664386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S; Davies E; Fearns S; McKinnon C; Carter R; Gerlinger C; Smithers A
    Clin Drug Investig; 2010; 30(5):325-36. PubMed ID: 20384388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism.
    Ågren UM; Anttila M; Mäenpää-Liukko K; Rantala ML; Rautiainen H; Sommer WF; Mommers E
    Eur J Contracept Reprod Health Care; 2011 Dec; 16(6):444-57. PubMed ID: 22066891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined oral contraceptive and nitric oxide synthesis inhibition synergistically causes cardiac hypertrophy and exacerbates insulin resistance in female rats.
    Olatunji LA; Olaniyi KS; Usman TO; Abolarinwa BA; Achile CJ; Kim IK
    Environ Toxicol Pharmacol; 2017 Jun; 52():54-61. PubMed ID: 28376377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged monitoring of ethinyl estradiol and levonorgestrel levels confirms an altered pharmacokinetic profile in obese oral contraceptives users.
    Edelman AB; Cherala G; Munar MY; Dubois B; McInnis M; Stanczyk FZ; Jensen JT
    Contraception; 2013 Feb; 87(2):220-6. PubMed ID: 23153898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
    Duijkers IJ; Klipping C; Verhoeven CH; Dieben TO
    Hum Reprod; 2004 Nov; 19(11):2668-73. PubMed ID: 15333593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined oral contraceptive interference with the ability of ulipristal acetate to delay ovulation: A prospective cohort study.
    Edelman AB; Jensen JT; McCrimmon S; Messerle-Forbes M; O'Donnell A; Hennebold JD
    Contraception; 2018 Dec; 98(6):463-466. PubMed ID: 30118684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral contraceptive use changes brain activity and mood in women with previous negative affect on the pill--a double-blinded, placebo-controlled randomized trial of a levonorgestrel-containing combined oral contraceptive.
    Gingnell M; Engman J; Frick A; Moby L; Wikström J; Fredrikson M; Sundström-Poromaa I
    Psychoneuroendocrinology; 2013 Jul; 38(7):1133-44. PubMed ID: 23219471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized trial of the effect of tailored versus standard use of the combined oral contraceptive pill on continuation rates at 1 year.
    Stephenson J; Shawe J; Panicker S; Brima N; Copas A; Sauer U; Wilkinson C; Akintomide H; O'Brien P
    Contraception; 2013 Oct; 88(4):523-31. PubMed ID: 23663917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of low-dose combined oral contraceptive containing 100 ug levonorgestrel on plasma plasminogen activator inhibitor-1 concentrations.
    Küçük M; Sezer SD; Odabaşi AR; Güner Z; Yuksel H; Serter M
    Clin Exp Obstet Gynecol; 2011; 38(1):54-6. PubMed ID: 21485727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of endogenous cortisol 6β-hydroxylation clearance for phenotyping in vivo CYP3A activity in women after sequential administration of an oral contraceptive (OC) containing ethinylestradiol and levonorgestrel as weak CYP3A inhibitors.
    Shibasaki H; Kuroiwa M; Uchikura S; Tsuboyama S; Yokokawa A; Kume M; Furuta T
    Steroids; 2014 Sep; 87():137-44. PubMed ID: 24928723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haemostatic and metabolic impact of estradiol pills and drospirenone-containing ethinylestradiol pills vs. levonorgestrel-containing ethinylestradiol pills: A literature review.
    Lete I; Chabbert-Buffet N; Jamin C; Lello S; Lobo P; Nappi RE; Pintiaux A
    Eur J Contracept Reprod Health Care; 2015; 20(5):329-43. PubMed ID: 26007631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of lersivirine, a next-generation NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects.
    Davis J; Langdon G; Layton G; Chong CL; Ndongo MN; Vourvahis M
    Eur J Clin Pharmacol; 2012 Nov; 68(11):1567-72. PubMed ID: 22527351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative Assessment of Levonorgestrel Binding Partner Interplay and Drug-Drug Interactions Using Physiologically Based Pharmacokinetic Modeling.
    Cicali B; Lingineni K; Cristofoletti R; Wendl T; Hoechel J; Wiesinger H; Chaturvedula A; Vozmediano V; Schmidt S
    CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):48-58. PubMed ID: 33217171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining the Exposure Threshold for Levonorgestrel Efficacy Using an Integrated Model Based Meta-Analysis Approach.
    Lingineni K; Chaturvedula A; Cicali B; Cristofoletti R; Wendl T; Hoechel J; Brown JD; Vozmediano V; Schmidt S
    Clin Pharmacol Ther; 2022 Feb; 111(2):509-518. PubMed ID: 34674227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The combined contraceptive vaginal ring (NuvaRing) and lipid metabolism: a comparative study.
    Tuppurainen M; Klimscheffskij R; Venhola M; Dieben TO
    Contraception; 2004 May; 69(5):389-94. PubMed ID: 15105061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.